May 15 |
ProMIS Neurosciences GAAP EPS of -$0.19
|
May 14 |
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
|
Apr 30 |
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
|
Apr 9 |
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
|
Apr 4 |
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
|
Apr 1 |
ProMIS Neurosciences reports FY results
|
Apr 1 |
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
|
Mar 11 |
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
|
Feb 22 |
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
|
Jan 22 |
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
|